Kremlin refrains from comments on media allegations about Tillerson’s possible resignationRussian Politics & Diplomacy July 25, 14:03
Kremlin comments on US potentially funneling weapons to KievRussian Politics & Diplomacy July 25, 13:45
Kremlin says Russia, US not negotiating renewal of adoptionsRussian Politics & Diplomacy July 25, 13:37
Russian Ice Hockey Federation to render assistance to banned forward ZaripovSport July 25, 13:27
Press review: Malorossiya as an EU taboo and Moldova’s animosity to Russian peacekeepersPress Review July 25, 13:00
Poll reveals most Russians familiar with Jehovah’s Witnesses support its banSociety & Culture July 25, 12:11
Lithuania keeps tipping off NATO allies on Russian-Chinese naval drills in Baltic SeaMilitary & Defense July 25, 12:02
ECHR rules Nemtsov’s convicted murderer should receive 6,000-euro compensationWorld July 25, 11:50
Ukrainian citizen sentenced to community service for wearing St. George ribbonSociety & Culture July 25, 11:04
TOKYO, July 5, 2017 /PRNewswire/. Anaeropharma Science, Inc., a company dedicated to the development of novel therapeutics to target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate Investment Limited and Seventure Partners' Health for Life Capital fund, and two existing investors, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital's managed fund. Anaeropharma will use the financing to accelerate the development of multiple programs based on its proprietary platform technology.
Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant "Bifidobacterium". This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant "Bifidobacterium" to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant "Bifidobacteria" are under active development.
CONTACT: (Mr.) Tetsuya Mishima, President & CEO, Anaeropharma Science, Inc., Tel: +81-3-5642-8081, Email: firstname.lastname@example.org